Related Experiment Video
Updated: Mar 17, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors
Natalia Moreno1, Kornelius Kerl2
1University Children's Hospital, Department of Hematology and Oncology, Münster, Germany.
Background/Aim:
Rhabdoid tumors (RT) are aggressive pediatric tumors, which show poor prognosis despite use of multimodal intensive therapy. In these tumors, several different oncogenic pathways and epigenetic regulators (like CDK4/6-cyclinD-Rb-signaling, EZH2, histone deacetylases) are contemporaneously deregulated as a consequence of biallelic SMARCB1/SNF5/INI1 alterations. Since these tumors are highly resistant to current therapies, alternative treatment strategies are urgently required.
Materials And Methods:
In this study, we evaluated cytotoxic effects (by MTT tests) of small molecular compounds, which specifically target these deregulated pathways, using either single-drug or combined approaches. Half-maximal inhibitory concentration (IC50) and combined index (CI) were calculated.
Results:
All target-directed inhibitors blocked cell growth of three different rhabdoid tumor cell lines in vitro. Several combinations of those target-specific drugs synergistically inhibited cell proliferation of rhabdoid tumors.
Conclusion:
Supporting earlier reports, combined target-directed approaches are a promising tool for the therapy of malignant rhabdoid tumors.
Insights
Targeted drug combinations show promise for treating aggressive pediatric rhabdoid tumors (RT). These novel therapies synergistically inhibit cancer cell growth, offering new hope against treatment-resistant forms of RT.
Area of Science:
- Pediatric Oncology
- Cancer Therapeutics
- Molecular Biology
Background:
- Malignant rhabdoid tumors (RT) are aggressive pediatric cancers with poor prognoses.
- RT exhibit deregulated oncogenic pathways and epigenetic regulators due to SMARCB1 alterations.
- Current therapies are often ineffective, necessitating novel treatment strategies.
Purpose of the Study:
- To evaluate the cytotoxic effects of small molecule inhibitors targeting deregulated pathways in RT.
- To assess the efficacy of single-drug versus combined drug approaches in vitro.
- To identify synergistic treatment strategies for malignant rhabdoid tumors.
Main Methods:
- MTT assays were used to determine the cytotoxic effects of small molecule compounds.
- Compounds targeted specific deregulated pathways in three distinct rhabdoid tumor cell lines.
- Half-maximal inhibitory concentration (IC50) and combined index (CI) were calculated to assess drug efficacy and synergy.
Main Results:
- All tested target-directed inhibitors effectively blocked rhabdoid tumor cell growth in vitro.
- Combinations of specific target-inhibiting drugs demonstrated synergistic effects on cell proliferation.
- These findings confirm the potential of targeting multiple pathways simultaneously.
Conclusions:
- Combined target-directed therapies represent a promising strategy for treating malignant rhabdoid tumors.
- Synergistic drug combinations offer a potential avenue to overcome treatment resistance in RT.
- Further research into these combined approaches is warranted for clinical application.
More Related Videos
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
